Sign in or create an account to add this stock to your watchlist.
About ChemoCentryx (NASDAQ:CCXI)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900
Debt
Debt-to-Equity Ratio0.18
Current Ratio1.95
Quick Ratio1.95
Price-To-Earnings
Trailing P/E Ratio35.53
Forward P/E Ratio-12.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$82.50 million
Price / Sales7.62
Cash Flow$0.3706 per share
Price / Cash34.51
Book Value$0.52 per share
Price / Book24.60
Profitability
EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net MarginsN/A
Return on Equity31.56%
Return on Assets9.03%
Miscellaneous
Employees66
Outstanding Shares49,150,000
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx (NASDAQ:CCXI) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company had revenue of $9.55 million for the quarter, compared to the consensus estimate of $9.10 million. View ChemoCentryx's Earnings History.
What price target have analysts set for CCXI?
4 analysts have issued 1-year target prices for ChemoCentryx's shares. Their forecasts range from $16.00 to $20.00. On average, they expect ChemoCentryx's stock price to reach $17.6667 in the next twelve months. View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (5/16/2018)
- 2. Cowen Inc analysts commented, "ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30." (8/8/2017)
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Insmed (INSM), Xencor (XNCR), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Spectrum Pharmaceuticals (SPPI) and Puma Biotechnology (PBYI).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
- Mr. William C. Fairey Jr., Exec. VP & COO (Age 53)
- Dr. Rajinder Singh, Sr. VP of Research (Age 51)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
Has ChemoCentryx been receiving favorable news coverage?
News stories about CCXI stock have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChemoCentryx earned a news impact score of 0.30 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 44.00 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (14.68%), BlackRock Inc. (5.23%), Wasatch Advisors Inc. (4.86%), Franklin Resources Inc. (3.44%), Farallon Capital Management LLC (1.93%) and Carmignac Gestion (0.79%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., BlackRock Inc., Spark Investment Management LLC, Unterberg Capital LLC, Trexquant Investment LP, Federated Investors Inc. PA and Landscape Capital Management L.L.C.. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Carmignac Gestion, PNC Financial Services Group Inc., Wasatch Advisors Inc., Millennium Management LLC, JPMorgan Chase & Co., Alps Advisors Inc. and American Century Companies Inc.. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $12.79.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $635.51 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
ChemoCentryx (NASDAQ:CCXI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for ChemoCentryx in the last 12 months. Their average twelve-month price target is $17.6667, suggesting that the stock has a possible upside of 38.13%. The high price target for CCXI is $20.00 and the low price target for CCXI is $16.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Buy |
| Consensus Rating Score: | 2.75 | 2.50 | 2.00 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.6667 | $16.00 | N/A | N/A |
| Price Target Upside: | 38.13% upside | 22.89% upside | N/A | N/A |
ChemoCentryx (NASDAQ:CCXI) Consensus Price Target History
ChemoCentryx (NASDAQ:CCXI) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
ChemoCentryx (NASDAQ:CCXI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ChemoCentryx (NASDAQ CCXI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 50.09%
ChemoCentryx (NASDAQ CCXI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2018 | Thomas J Schall | Insider | Sell | 92,798 | $12.84 | $1,191,526.32 | 2,218,932 |  |
| 5/21/2018 | Markus J Cappel | Insider | Sell | 2,709 | $13.00 | $35,217.00 | 26,535 | |
| 5/21/2018 | Thomas J Schall | CEO | Sell | 33,938 | $12.55 | $425,921.90 | 2,218,932 | |
| 5/17/2018 | Thomas J Schall | Insider | Sell | 200,000 | $11.78 | $2,356,000.00 | 2,284,994 | |
| 5/16/2018 | Markus J Cappel | Treasurer | Sell | 50,000 | $11.81 | $590,500.00 | 40,492 | |
| 5/15/2018 | Susan M Kanaya | CFO | Sell | 8,306 | $11.14 | $92,528.84 | 46,441 | |
| 5/15/2018 | Thomas J Schall | CEO | Sell | 100,000 | $11.32 | $1,132,000.00 | 2,284,994 | |
| 5/8/2018 | Susan M Kanaya | CFO | Sell | 65,328 | $11.53 | $753,231.84 | 103,463 | |
| 5/2/2018 | Markus J Cappel | Insider | Sell | 50,000 | $11.02 | $551,000.00 | 35,737 | |
| 5/2/2018 | Susan M Kanaya | CFO | Sell | 1,366 | $11.50 | $15,709.00 | 39,501 | |
| 5/1/2018 | Thomas J Schall | CEO | Sell | 17,127 | $11.00 | $188,397.00 | 2,202,121 | |
| 8/1/2017 | Roger C Lucas | Director | Sell | 2,250 | $10.07 | $22,657.50 | 93,846 | |
| 7/13/2017 | Petrus Bekker | Insider | Sell | 76,013 | $9.95 | $756,329.35 | 65,963 | |
| 7/12/2017 | Petrus Bekker | Insider | Sell | 30,000 | $9.98 | $299,400.00 | 65,963 | |
| 7/11/2017 | Petrus Bekker | Insider | Sell | 30,000 | $9.78 | $293,400.00 | 65,963 | |
| 7/10/2017 | Petrus Bekker | Insider | Sell | 19,877 | $9.30 | $184,856.10 | 79,426 | |
| 6/30/2017 | Petrus Bekker | Insider | Sell | 65,509 | $9.17 | $600,717.53 | 89,839 | |
| 5/1/2017 | Roger C Lucas | Director | Sell | 4,000 | $7.31 | $29,240.00 | 62,822 | |
| 1/3/2017 | Markus J Cappel | Insider | Sell | 26,821 | $7.51 | $201,425.71 | 20,833 | |
| 12/16/2016 | Petrus Bekker | Insider | Sell | 8,712 | $8.74 | $76,142.88 | 55,638 | |
| 12/5/2016 | Petrus Bekker | Insider | Sell | 30,000 | $8.50 | $255,000.00 | 83,594 | |
| 11/22/2016 | Petrus Bekker | Insider | Sell | 1,250 | $8.30 | $10,375.00 | 54,844 | |
| 11/11/2016 | Petrus Bekker | Insider | Sell | 33,332 | $8.00 | $266,656.00 | 54,228 | |
| 9/1/2016 | Roger C Lucas | Director | Sell | 4,000 | $5.07 | $20,280.00 | 74,822 | |
| 5/23/2016 | James L Tyree | Director | Sell | 5,544 | $4.39 | $24,338.16 | 26,119 | |
| 5/17/2016 | Thomas A Edwards | Director | Buy | 50,000 | $4.05 | $202,500.00 | 91,977 | |
| 5/16/2016 | Thomas A Edwards | Director | Buy | 25,000 | $4.05 | $101,250.00 | 41,977 | |
| 5/13/2016 | Geoffrey M Parker | Director | Buy | 40,000 | $4.03 | $161,200.00 | 13,514 | |
| 1/22/2016 | Susan M. Kanaya | CFO | Sell | 25,764 | $4.04 | $104,086.56 | | |
| 1/20/2016 | Susan M. Kanaya | CFO | Sell | 14,971 | $4.10 | $61,381.10 | | |
| 1/19/2016 | Susan M. Kanaya | CFO | Sell | 6,134 | $4.05 | $24,842.70 | | |
| 1/15/2016 | Susan M. Kanaya | CFO | Sell | 300 | $4.00 | $1,200.00 | | |
| 1/11/2016 | Geoffrey M Parker | Director | Buy | 20,000 | $4.63 | $92,600.00 | 13,514 | |
| 1/8/2016 | Susan M. Kanaya | CFO | Sell | 10,224 | $5.12 | $52,346.88 | | |
| 1/6/2016 | Susan M. Kanaya | CFO | Sell | 47,607 | $6.98 | $332,296.86 | | |
| 1/5/2016 | Susan M. Kanaya | CFO | Sell | 34,341 | $6.90 | $236,952.90 | | |
| 1/4/2016 | Susan M. Kanaya | CFO | Sell | 10,490 | $7.38 | $77,416.20 | | |
| 12/11/2015 | Geoffrey M Parker | Director | Buy | 20,000 | $7.25 | $145,000.00 | 13,514 | |
| 11/4/2015 | Value Fund L P Biotechnology | Insider | Sell | 360,000 | $7.00 | $2,520,000.00 | | |
| 11/2/2015 | Value Fund L P Biotechnology | Insider | Sell | 50,000 | $6.97 | $348,500.00 | | |
| 6/10/2015 | Bvf Partners L P/Il | Major Shareholder | Sell | 955,700 | $9.00 | $8,601,300.00 | | |
| 5/22/2015 | Ira Klein | Director | Sell | 10,811 | $7.44 | $80,433.84 | | |
| 4/1/2015 | Thomas J Schall | CEO | Sell | 24,267 | $7.50 | $182,002.50 | | |
| 3/31/2015 | Thomas J Schall | CEO | Sell | 16,540 | $7.55 | $124,877.00 | | |
| 3/30/2015 | Thomas J Schall | CEO | Sell | 1,200 | $7.51 | $9,012.00 | | |
| 3/24/2015 | Thomas J Schall | CEO | Sell | 50,371 | $7.84 | $394,908.64 | | |
| 3/19/2015 | Thomas J Schall | CEO | Sell | 18,146 | $8.34 | $151,337.64 | | |
| 3/17/2015 | Thomas J Schall | CEO | Sell | 31,316 | $8.55 | $267,751.80 | | |
| 3/9/2015 | Markus J Cappel | Treasurer | Sell | 34,125 | $7.81 | $266,516.25 | | |
| 3/4/2015 | Markus J Cappel | Treasurer | Sell | 40,875 | $7.98 | $326,182.50 | | |
| 3/3/2015 | Markus J Cappel | Treasurer | Sell | 5,943 | $7.81 | $46,414.83 | | |
| 3/2/2015 | Markus J Cappel | Treasurer | Sell | 14,390 | $8.13 | $116,990.70 | | |
| 11/18/2014 | Anne-Marie Duliege | EVP | Sell | 4,970 | $4.71 | $23,408.70 | | |
| 5/1/2014 | Thomas J Schall | CEO | Sell | 27,726 | $5.59 | $154,988.34 | | |
| 4/29/2014 | Thomas J Schall | CEO | Sell | 32,274 | $5.38 | $173,634.12 | | |
| 4/22/2014 | Markus J Cappel | Treasurer | Sell | 20,962 | $8.17 | $171,259.54 | | |
| 3/17/2014 | Thomas J Schall | CEO | Sell | 20,000 | $7.25 | $145,000.00 | | |
| 12/6/2013 | Geoffrey M Parker | Director | Buy | 20,000 | $5.15 | $103,000.00 | | |
| 12/5/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 189,800 | $5.01 | $950,898.00 | | |
| 11/6/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 136,066 | $4.92 | $669,444.72 | | |
| 11/1/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 336,225 | $4.99 | $1,677,762.75 | | |
| 10/9/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 1,289,354 | $5.34 | $6,885,150.36 | | |
| 10/3/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 109,425 | $5.49 | $600,743.25 | | |
| 9/13/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 325,635 | $5.95 | $1,937,528.25 | | |
| 9/13/2013 | Joseph M Feczko | Director | Buy | 10,000 | $6.03 | $60,300.00 | | |
| 8/13/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $12.90 | $70,421.10 | | |
| 8/7/2013 | Petrus Bekker | SVP | Sell | 5,000 | $13.26 | $66,300.00 | | |
| 8/5/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.42 | $67,100.00 | | |
| 8/1/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.82 | $86,375.00 | | |
| 7/17/2013 | Markus J Cappel | Treasurer | Sell | 5,459 | $14.52 | $79,264.68 | | |
| 7/17/2013 | Petrus Bekker | SVP | Sell | 10,000 | $14.54 | $145,400.00 | | |
| 7/16/2013 | Thomas J Schall | CEO | Sell | 22,089 | $14.39 | $317,860.71 | | |
| 7/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.43 | $67,150.00 | | |
| 7/2/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.88 | $86,750.00 | | |
| 6/28/2013 | Susan M Kanaya | CFO | Sell | 36,942 | $14.31 | $528,640.02 | | |
| 6/27/2013 | Petrus Bekker | SVP | Sell | 5,000 | $14.00 | $70,000.00 | | |
| 6/21/2013 | Markus J Cappel | Treasurer | Sell | 6,250 | $13.00 | $81,250.00 | | |
| 6/18/2013 | Markus J Cappel | Treasurer | Sell | 1,783 | $12.47 | $22,234.01 | | |
| 6/17/2013 | Petrus Bekker | SVP | Sell | 5,000 | $12.00 | $60,000.00 | | |
| 6/3/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.32 | $66,600.00 | | |
| 5/30/2013 | Susan M Kanaya | CFO | Sell | 12,770 | $14.28 | $182,355.60 | | |
| 5/28/2013 | Markus J Cappel | Treasurer | Sell | 3,676 | $14.10 | $51,831.60 | | |
| 5/24/2013 | Petrus Bekker | SVP | Sell | 4,800 | $14.00 | $67,200.00 | | |
| 5/17/2013 | Petrus Bekker | SVP | Sell | 15,000 | $13.97 | $209,550.00 | | |
| 5/15/2013 | Markus J Cappel | Treasurer | Sell | 15,668 | $14.08 | $220,605.44 | | |
| 5/15/2013 | Roger C Lucas | Director | Sell | 5,000 | $14.11 | $70,550.00 | | |
| 5/15/2013 | Thomas J Schall | CEO | Sell | 7,600 | $14.04 | $106,704.00 | | |
| 4/11/2013 | Markus J Cappel | Treasurer | Sell | 1,500 | $14.10 | $21,150.00 | | |
| 4/11/2013 | Petrus Bekker | SVP | Sell | 3,979 | $14.03 | $55,825.37 | | |
| 4/11/2013 | Thomas J Schall | CEO | Sell | 2,529 | $14.02 | $35,456.58 | | |
| 3/6/2013 | Petrus Bekker | SVP | Sell | 11,502 | $13.98 | $160,797.96 | | |
| 3/6/2013 | Thomas J Schall | CEO | Sell | 5,541 | $14.01 | $77,629.41 | | |
| 3/4/2013 | Roger C Lucas | Director | Sell | 5,000 | $13.87 | $69,350.00 | | |
| 2/26/2013 | Juan C Jaen | SVP | Sell | 22,500 | $12.23 | $275,175.00 | | |
| 2/22/2013 | Thomas J Schall | CEO | Sell | 7,500 | $12.06 | $90,450.00 | | |
| 2/6/2013 | Roger C Lucas | Director | Sell | 3,857 | $11.52 | $44,432.64 | | |
| 2/4/2013 | Juan C Jaen | SVP | Sell | 3,875 | $11.69 | $45,298.75 | | |
| 1/17/2013 | Markus J Cappel | Treasurer | Sell | 2,700 | $11.16 | $30,132.00 | | |
| 11/6/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 40,000 | $12.00 | $480,000.00 | | |
| 10/4/2012 | Roger C Lucas | Director | Sell | 1,893 | $11.47 | $21,712.71 | | |
| 10/1/2012 | Susan M Kanaya | CFO | Sell | 3,971 | $11.89 | $47,215.19 | | |
| 10/1/2012 | Thomas J Schall | CEO | Sell | 15,000 | $11.53 | $172,950.00 | | |
(Data available from 1/1/2013 forward)
ChemoCentryx (NASDAQ CCXI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Form 4 ChemoCentryx, Inc. For: May 21 Filed by: Edwards Thomas A.
www.streetinsider.com - May 24 at 5:46 PM |
| Form 4 ChemoCentryx, Inc. For: May 21 Filed by: Parker Geoffrey M.
www.streetinsider.com - May 24 at 8:16 AM |
| Form 4 ChemoCentryx, Inc. For: May 21 Filed by: Tyree James L
www.streetinsider.com - May 24 at 8:16 AM |
 | Insider Selling: ChemoCentryx (CCXI) Insider Sells 2,709 Shares of Stock
www.americanbankingnews.com - May 23 at 10:44 PM |
| ChemoCentryx (CCXI) CEO Sells $425,921.90 in Stock
www.americanbankingnews.com - May 23 at 10:26 PM |
| ChemoCentryx (CCXI) Insider Thomas J. Schall Sells 92,798 Shares
www.americanbankingnews.com - May 23 at 10:26 PM |
 | ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress
finance.yahoo.com - May 23 at 5:39 PM |
| ChemoCentryx (CCXI) Expected to Post Quarterly Sales of $9.58 Million
www.americanbankingnews.com - May 20 at 2:30 AM |
| -$0.25 EPS Expected for ChemoCentryx (CCXI) This Quarter
www.americanbankingnews.com - May 18 at 5:14 PM |
| Form 4 ChemoCentryx, Inc. For: May 15 Filed by: KANAYA SUSAN M
www.streetinsider.com - May 18 at 8:29 AM |
| ChemoCentryx (CCXI) CFO Susan M. Kanaya Sells 8,306 Shares
www.americanbankingnews.com - May 17 at 10:44 PM |
| Insider Selling: ChemoCentryx (CCXI) Insider Sells 200,000 Shares of Stock
www.americanbankingnews.com - May 17 at 10:26 PM |
| Insider Selling: ChemoCentryx (CCXI) Treasurer Sells 50,000 Shares of Stock
www.americanbankingnews.com - May 17 at 10:26 PM |
| ChemoCentryx (CCXI) CEO Thomas J. Schall Sells 100,000 Shares
www.americanbankingnews.com - May 17 at 10:26 PM |
| Can The Uptrend Continue for ChemoCentryx (CCXI)?
finance.yahoo.com - May 17 at 6:50 PM |
| ChemoCentryx (CCXI) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - May 16 at 8:19 PM |
| ChemoCentryx (CCXI) Coverage Initiated at Canaccord Genuity
www.americanbankingnews.com - May 16 at 2:28 PM |
| ChemoCentryx (CCXI) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - May 16 at 11:04 AM |
| ChemoCentryx (CCXI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 13 at 9:03 AM |
| ChemoCentryx (CCXI) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 11 at 5:45 PM |
| ChemoCentryx (CCXI) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - May 10 at 9:37 PM |
| Insider Selling: ChemoCentryx (CCXI) CFO Sells 65,328 Shares of Stock
www.americanbankingnews.com - May 10 at 7:35 PM |
 | ChemoCentryx's (CCXI) CEO Dr. Thomas Schall on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:19 AM |
| ChemoCentryx: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:19 AM |
| Edited Transcript of CCXI earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 8:19 AM |
 | BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million
www.reuters.com - May 9 at 5:38 PM |
| ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - May 9 at 5:38 PM |
| Form 4 ChemoCentryx, Inc. For: May 02 Filed by: KANAYA SUSAN M
www.streetinsider.com - May 5 at 8:21 AM |
| ChemoCentryx (CCXI) CFO Susan M. Kanaya Sells 1,366 Shares
www.americanbankingnews.com - May 4 at 8:15 PM |
| Form 4 ChemoCentryx, Inc. For: May 01 Filed by: Cappel Markus J.
www.streetinsider.com - May 4 at 5:37 PM |
| Form 4 ChemoCentryx, Inc. For: May 01 Filed by: Schall Thomas J.
www.streetinsider.com - May 4 at 8:16 AM |
| ChemoCentryx (CCXI) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM |
| Insider Selling: ChemoCentryx (CCXI) Insider Sells 50,000 Shares of Stock
www.americanbankingnews.com - May 3 at 10:15 PM |
| Thomas J. Schall Sells 17,127 Shares of ChemoCentryx (CCXI) Stock
www.americanbankingnews.com - May 3 at 10:15 PM |
 | Benzinga's Top Upgrades, Downgrades For May 2, 2018
www.benzinga.com - May 2 at 5:39 PM |
| ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018
finance.yahoo.com - May 2 at 5:39 PM |
| ChemoCentryx (CCXI) Now Covered by HC Wainwright
www.americanbankingnews.com - May 2 at 11:10 AM |
| -$0.29 EPS Expected for ChemoCentryx (CCXI) This Quarter
www.americanbankingnews.com - May 1 at 5:22 AM |
| Free Research Report as ChemoCentryx’s Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
finance.yahoo.com - April 19 at 8:12 AM |
| ChemoCentryx (CCXI) Upgraded at TheStreet
www.americanbankingnews.com - April 18 at 10:41 AM |
| ChemoCentryx (CCXI) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 9:56 AM |
| ChemoCentryx (CCXI) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - April 17 at 11:37 AM |
| Zacks: ChemoCentryx (CCXI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 16 at 5:19 PM |
| ChemoCentryx (CCXI) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 14 at 7:41 AM |
| ChemoCentryx (CCXI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM |
| Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio?
finance.yahoo.com - April 13 at 8:16 AM |
| ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
finance.yahoo.com - April 11 at 5:35 PM |
| Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 10 at 8:20 AM |
| Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry?
finance.yahoo.com - April 4 at 4:16 PM |
 | Active-Investors: Wired News - Exelixis' Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
www.finanznachrichten.de - April 2 at 8:33 AM |
ChemoCentryx (NASDAQ:CCXI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ChemoCentryx (NASDAQ:CCXI) Income Statement, Balance Sheet and Cash Flow Statement
ChemoCentryx (NASDAQ CCXI) Stock Chart for Saturday, May, 26, 2018
Loading chart…
